Document:

EX-10.31

 Exhibit 10.31 

EXECUTION COPY 
 RELIEF
THERAPEUTICS / NEURORX 
 BINDING COLLABORATION AGREEMENT 

This Binding Collaboration Agreement (this “Agreement”), dated as of September 18, 2020 outlines the terms and conditions of the Collaboration
(defined below) between Relief Therapeutics Holding Aktiengesellschaft and its wholly owned subsidiary Therametrics Discovery Aktiengesellschaft (collectively, “Relief”), Swiss corporations, and NeuroRx, Inc. (“NeuroRx”), a
Delaware corporation (each a “Party” and, collectively, the “Parties”). The Parties hereby acknowledge and agree that the terms set forth in that certain Non-Disclosure Agreement between
the Parties, dated as of September 9, 2020, apply to the terms set forth herein. 
  

	1.	 Definitions 

 

	 	1.	 “Affiliate” means, with respect to any Person, another Person which controls, is controlled by or is
under common control with such Person. A Person shall be deemed to control another Person if such Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the
ownership of voting securities, by contract or otherwise. Without limiting the generality of the foregoing, a Person shall be deemed to control another Person if any of the following conditions is met: (a) in the case of corporate entities,
direct or indirect ownership of at least 50% of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate entities, direct or indirect ownership of at least 50% of the equity interest with
the power to direct the management and policies of such non-corporate entities. The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United
States, the maximum percentage ownership permitted by law for a foreign investor may be less than 50%, and that in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to
direct the management and policies of such entity. For purposes of this Agreement, in no event shall Relief or any of its Affiliates be deemed Affiliates of NeuroRx or any of its Affiliates, nor shall NeuroRx or any of its Affiliates be deemed
Affiliates of Relief or any of its Affiliates. 

  

	 	2.	 “BARDA” means the United States Biomedical Advanced Research and Development Authority.

  

	 	3.	 “CMC” means chemistry, manufacturing and controls. 

 

	 	4.	 “CMO” means contract manufacturing organization. 

 

	 	5.	 “Collaboration” means the development and commercialization of the Product as contemplated under this
Agreement. 

  

	 	6.	 “Commercialization Plan” means a commercial plan for the Product. 

 

	 	7.	 “COVID-19” means disease, condition, or ailment caused by,
associated with, or reasonably related to, the novel 2019 coronavirus. 

  

							
	 	 	 	 	 Page  |
	  	1

	 	8.	 “Development Plan” means a written development plan mutually agreed by the Parties.

  

	 	9.	 “Dr. Javitt” means Jonathan C. Javitt, M.D., M.P.H. 

 

	 	10.	 “EU” means the European Union, as its membership may be constituted from time to time and any
successor thereto. 

  

	 	11.	 “FDA” means the United States Food and Drug Administration or any successor entity thereto.

	 	

	 	12.	 “Information” means any and all materials, data and other information relating to the subject matter
of this Agreement and including: (a) techniques and data, including screens, models, inventions, methods, test data (including, pharmacological, toxicological and clinical test data), analytical and quality control data, marketing, pricing,
distribution, costs, and sales data, manufacturing information, and patent and legal data or descriptions (to the extent that disclosure thereof would not result in loss or waiver of privilege or similar protection); (b) compositions of matter,
including compounds, biological materials and assays; and (c) the subject matter and content of all discussions and meetings between the Parties regarding the subject matter of this Agreement, in each case, whether or not patentable or
copyrightable or subject to protection under applicable trade secret law. As used herein, “clinical test data” shall be deemed to include all information related to the clinical or preclinical testing of the Product, including patient
report forms, investigators’ reports, biostatistical, pharmacoeconomic and other related analyses, regulatory filings and communications, and similar data, documentation and information. 

 

	 	13.	 “Intellectual Property” or “IP” means any and all intellectual property rights and similar
proprietary rights, including Patents, trademarks, copyrights and Information, whether registered or unregistered, and all applications and registrations to register, and renewals and extensions of, any of the foregoing in any jurisdiction.

  

	 	14.	 “JSC” means a joint steering committee. 

 

	 	15.	 “Licensee Party” means a Party to this Agreement is receiving from the other Party to the Agreement a
license to IP. 

  

	 	16.	 “Licensor Party” means a Party to this Agreement that is granting the other Party to this Agreement a
license to IP. 

  

	 	17.	 “Loss” means any payment, cost, damage, disbursement, expense, loss, liability, deficiency, lost
profit, diminution in value, interest, penalties, costs or expenses (including reasonable outside legal, accounting and other professional fees). 

  

	 	18.	 “MOA” means mechanism of action. 

 

	 	19.	 “NDA” means New Drug Application. 

 

	 	20.	 “Net Profits” means gross cash revenue actually received by NeuroRx or Relief, as applicable, for
sales of the Product, less all costs and expenses, direct and indirect, incurred or borne by or on behalf of NeuroRx or Relief, respectively, arising in connection with any such sales of the Product. These costs include (but are not limited to), for
example, all (i) normal and customary trade and quantity discounts, (ii) reasonable discounts, allowances, credits, chargebacks and refunds (e.g., for any nonconforming, damaged, rejected, outdated, returned,

  

							
	 	 	 	 	 Page  |
	  	2

	 	
withdrawn or recalled Product), (iii) rebates and price reductions and adjustments required by any applicable law or regulation or contract, (iv) sales, value added, excise and all other
taxes and duties and any other governmental charges imposed upon the importation or sale of the Product, (v) damages or other losses arising out of or resulting from Third Party claims, (vi) overhead, labor, equipment, warehousing,
storage, logistics, freight and transport costs and expenses, and (vii) royalties paid to third parties. In the case of any sale of the Product for consideration other than cash, such as barter or countertrade, Net Profits shall be calculated
assuming the fair market value of the consideration received as agreed by the Parties, each acting reasonably and in good faith. The foregoing definition and all financial definitions herein shall be determined in accordance with generally accepted
accounting principles as applicable in the United States, or similar accounting principles in Switzerland if applicable, as generally and consistently applied. 

  

	 	21.	 “NeuroRx Territory” means the U.S., Canada, and Israel (and, as applicable, all territories and
possessions of any of the foregoing). 

  

	 	22.	 “NIH” means the United States National Institutes of Health. 

 

	 	23.	 “Patents” means any patents and patent applications, together with all additions, divisionals,
continuations, continuations-in-part, substitutions, reissues, re-examinations, extensions, registrations, patent term
extensions, supplemental protection certificates and renewals of any of the foregoing, and all foreign counterparts thereof in any jurisdiction. 

  

	 	24.	 “Person” means and includes any individual, partnership, joint venture, limited liability company,
corporation, firm, trust, unincorporated organization and government or other department or agency thereof. 

  

	 	25.	 “Product” means aviptadil (also known as RLF-100 or a drug
name mutually agreed upon by the Parties and approved by the FDA) for any route of administration, including intravenous and inhaled use, as long as Relief funds the research and development costs for developing such use. Relief may use a different
brand name in the Relief Territory (as defined below). 

  

	 	26.	 “Regulatory Agency” means the FDA or any regulatory body with similar regulatory authority in the
United States or any jurisdiction outside the United States. 

  

	 	27.	 “Regulatory Exclusivity” means any exclusive marketing authority conveyed by a Regulatory
Agency that precludes generic competition. 

  

	 	28.	 “Regulatory License” means any marketing authority conveyed by a New Drug Approval, Emergency Use
Authorization, fast track approval, or their equivalents granted by a Regulatory Agency. 

  

	 	29.	 “Relief Territory” means the EU, Switzerland, Iceland, Norway, the UK, the Channel Islands,
Liechtenstein, Monaco, Andorra, Malta, San Marino, and Vatican City (and, as applicable, all territories and possessions of any of the foregoing). 

  

	 	30.	 “Revenues” means net sales, together with any other consideration or payments received in connection
with the present or future commercialization or licensing of the Product, including license and sublicense fees and milestone payments. 

  

							
	 	 	 	 	 Page  |
	  	3

	 	31.	 “ROW Countries” means all countries (and, as applicable, all territories and possessions of any of
the foregoing) other than those included in the NeuroRx Territory or the Relief Territory. 

  

	 	32.	 “Territory” means, in reference to Relief, the Relief Territory and, in reference to NeuroRx, the
NeuroRx Territory. 

  

	 	33.	 “Third Party” means any Person other than either Party or any of its respective Affiliates.

  

	 	34.	 “U.S.” and “United States” means the United States (including its territories and
possessions) and Puerto Rico. 

  

	 	35.	 “Weekly Call” means a recurring weekly call on a day and time to be mutually agreed to by the
Parties, the purpose of which will be for the Parties to discuss the Product, the Collaboration and other related matters. 

  

	2.	 Scope of Collaboration Between Relief and NeuroRx 

 

	 	2.1	 NeuroRx and Relief agree that the execution of this Agreement grants each Party complete freedom to operate
under the other’s Intellectual Property pertaining to the Product in their respective Territories. Should additional documents be required in the future to perfect this provision, the Parties agree to promptly execute such documents. In the
event the Parties are unable to agree upon the terms and conditions of such documents, counsel to each Party shall jointly appoint an arbitrator who will prepare any required documents. 

 

	 	2.2	 NeuroRx and Relief will collaborate to assist each other in maximizing sales and revenues from the Product in
their respective Territories. 

  

	 	2.3	 NeuroRx will lead and have control over the U.S. clinical effort on the Product, subject to the terms set forth
herein; and NeuroRx will have control over commercialization of the Product in the NeuroRx Territory, subject to the terms set forth herein. Relief will have control over commercialization of the Product in the Relief Territory, subject to the terms
set forth herein. In the event that there exists a conflict between this Section 2.3 and any other provision in this Agreement, Section 2.3 shall control. 

 

	 	2.4	 The Parties acknowledge and agree that the Collaboration will allow both Parties to better use their existing
assets than they would be able to absent the Collaboration. The Collaboration will enable the development and commercialization of the Product to treat COVID-19 faster and more efficiently than would be
possible absent the Collaboration. 

  

	3.	 Assets to be Utilized in the Collaboration 

 

	 	•	 	 Relief Assets to be utilized in the Collaboration include: 

 

	 	•	 	 Cash or cash equivalents required to continue providing sole funding of the Collaboration; 

 

	 	•	 	 Product drug substance; 

 

	 	•	 	 U.S. Patent No. 8,178,489, related Patents derived from U.S. Patent Application Serial No. 11/817,867
and foreign formulation Patents; 

  

	 	•	 	 U.S. and European Union Orphan Drug Designations related to ARDS, sarcoidosis, and pulmonary hypertension;

  

	 	•	 	 EU-compliant and possibly U.S.-compliant toxicity file and pre-clinical data; and 

  

							
	 	 	 	 	 Page  |
	  	4

	 	•	 	 Clinical Phase 2 data from prior in-human trials conducted in the EU:

  

	 	•	 	 Pulmonary fibrosis (failed); 

 

	 	•	 	 Pulmonary hypertension (failed); and 

 

	 	•	 	 Sarcoidosis (+ intermediate endpoint). 

 

	 	•	 	 NeuroRx Assets to be utilized in the Collaboration include: 

 

	 	•	 	 Regulatory Information; 

 

	 	•	 	 Existing U.S. corporation and expertise in U.S. corporate matters; 

 

	 	•	 	 Current authorized United States IND applications that may be used to intravenously deliver the Product in
critical COVID-19 cases; 

  

	 	•	 	 Current authorized United States IND for inhaled use of the Product in moderate and severe COVID-19 cases; 

  

	 	•	 	 GCP clinical trial structure with multiple qualified study sites, a Data Monitoring Committee, Advarra IRB,
active protocols, and substantial ongoing data collection; 

  

	 	•	 	 IBM Watson grant for transition to IBM Watson electronic data capture system; 

 

	 	•	 	 cGMP formulation and stability data for the Product, sterile product for intravenous and inhaled use;

  

	 	•	 	 Information regarding manufacturing techniques required to ensure potency of the Product; 

 

	 	•	 	 Ongoing relationship with Operation Warp Speed, NIH, BARDA, and State organizations and related documents,
correspondence, submissions and other materials pertaining thereto; 

  

	 	•	 	 Information included or embodied in United States IND 149,152 or United States IND 151,070 and related documents
filed, and correspondence and submissions with, the FDA and other materials pertaining thereto; 

  

	 	•	 	 Qualification through SAMS as a qualified USG entity; and 

 

	 	•	 	 Teaming agreements as a SAMS-qualified entity with the Henry Jackson Foundation, ICONgphs, and other BARDA
preferred partners. 

  

	4.	 Development Plan and Budget 

 

	 	4.1.	 NeuroRx shall direct, design and implement the entire pathway for U.S. drug approval for the Product (the
“Project”). 

  

	 	4.2.	 NeuroRx shall be the designated party to all contractual agreements related to the manufacture and marketing of
the Product in the NeuroRx Territory with external service providers and the sole named entity on all invoices related to activities associated with the Project. If Relief now or in the future chooses a commercialization partner other than NeuroRx
in the NeuroRx Territory pursuant to Section 8.11 hereof, NeuroRx will assign all contractual agreements and Regulatory Licenses to Relief’s chosen commercialization partner. 

 

	 	4.3.	 Relief shall be the designated party to all contractual agreements related to the manufacture and marketing of
the Product outside the NeuroRx Territory with external service providers and the sole named entity on all invoices related to activities associated with the pathway for marketing approval for the Product outside NeuroRx Territory.

  

	 	4.4.	 NeuroRx is responsible for ensuring that all activities undertaken under the Project (a) comply with the
Development Plan, (b) do not exceed 30% of the budget contemplated by Relief’s Board of Directors on March 22, 2020 (as may be amended by the written agreement of Relief and NeuroRx) and (c) comply with all applicable laws.

  

							
	 	 	 	 	 Page  |
	  	5

	 	4.5.	 Given that Relief is a 50% partner in Net Profits earned in the NeuroRx Territory, all individual employees
paid in excess of $500,000 shall be reasonably acceptable to Relief, such agreement not to be unreasonably withheld or delayed. 

  

	 	4.6.	 The Parties recognize that the March 22, 2020 budget did not contemplate the costs that have been incurred
for drug formulation, manufacture, CMC, stability, etc., which costs have been funded by Relief. 

	 	

	 	4.7.	 Material updates or changes to the Development Plan or the budget (i.e., increased costs in the aggregate which
exceed 30%) for the Project shall be approved by Relief’s Board of Directors, which shall not be unreasonably withheld or delayed. 

  

	 	4.8.	 Each of NeuroRx and Relief shall refrain from contacting any representative of any service provider, supplier
or vendor in the NeuroRx Territory, in the case of Relief, and in the Relief Territory, in the case of NeuroRx, engaged or otherwise involved in the Project (including any and all service providers, suppliers and vendors involved in the performance
of clinical development activities associated with the Product) in a manner that is reasonably likely to have a material and adverse effect on the Project without providing the other Party with reasonable prior written notice and the opportunity to
participate in discussions and negotiations therewith; provided that NeuroRx shall not be obligated to provide such advance notice or opportunity to participate to Relief solely to the extent such contact is imminently necessary to provide patient
care and provided that NeuroRx provides notice to Relief of such contact immediately thereafter. 

  

	 	4.9.	 Revenues from grants, Priority Review Vouchers, or any other similar sources, shall be divided between the
Parties as follows: in the NeuroRx Territory 50/50 and in the Relief Territory 85/15, and on an 80/20 basis in Relief’s favor in the ROW Countries. 

  

	5.	 Exclusivity and Cooperation 

 

	 	5.1.	 Unless otherwise provided herein, each of NeuroRx and Relief shall refrain from, and shall use commercially
reasonable efforts to cause its Affiliates to refrain from, directly or indirectly (which for the avoidance of doubt shall include via any Person that is an equity holder of any of the foregoing) engaging in any development activities for, or
conducting any unilateral bids to identify or solicit bids from contract manufacturers to synthesize or formulate, any drug or any related substance, product or treatment intended to be used to treat, combat, ameliorate, prevent or mitigate the
effects of COVID-19 or any ailment reasonably related thereto that does or could reasonably be expected to compete against or reduce sales (or other monetization) of the Product. To the extent NeuroRx or any
of its Affiliates controls any Third Party that are related to the Product or the development of the Product, this restriction shall also apply to each such Third Party. 

 

	 	5.2.	 It is acknowledged and agreed that each Party retains the right to develop and own IP that is not related to
the Collaboration in any way, and Relief retains the freedom to operate and in-license the development of treatments for indications other than COVID-19 that use the
same or a different MOA than the Product. 

  

	 	5.3.	 Relief may elect to fund all expenses associated with RLF-100 and/or
related molecules in areas outside COVID-19. Should Relief elect to do so, NeuroRx will have the option to participate in the clinical and regulatory development of the drug and/or related molecules in those
areas, but if it does not exercise its option to participate (i.e., within 30 days of receipt of written notice by 

  

							
	 	 	 	 	 Page  |
	  	6

	 	
Relief of its initiation of development programs in those areas), then Relief shall be entitled to select a different development partner or conduct the work itself, without further obligation to
NeuroRx with respect to future sales of the drug and/or related molecules in those indications. NeuroRx shall receive an opt-in right if it is involved with the clinical and regulatory development of the drug
and/or related molecules in these non-COVID-19 indications, and if NeuroRx exercises such an opt-in right for those indications
in its Territories (namely, the United States, Israel and Canada), it shall be entitled to 50% of the Net Profits in those areas if it commercializes the drug and/or related molecules for those indications. If NeuroRx does not exercise its opt-in right (i.e., within 30 days of written notice by Relief of the release of positive clinical data from those studies), then it shall not be entitled to any revenue split whatsoever. Relief shall own all rights
to all Revenues and Net Profits in areas outside the NeuroRx Territory and shall fund and conduct all development, regulatory and commercial costs in those areas. 

 

	 	5.4.	 If NeuroRx or any of its Affiliates seeks to develop itself or collaborate with another Person on any treatment
for acute respiratory distress syndrome, acute lung injury, asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, sarcoidosis, and influenza, regardless of MOA, which, in each case, is
non-COVID related, then: (a) if Relief provides all funding, it shall be entitled to 50% of NeuroRx’s Net Profits, and (b) if Relief does not provide all funding, it shall be entitled to 2.5% of
NeuroRx’s Net Profits. 

  

	 	5.5.	 Each of NeuroRx and Relief agree to work cooperatively to enhance the value of the Product through the pursuit
of business development initiatives, including solicitation of partnership or distribution arrangements aimed at facilitating the advancement and commercialization of the Product. Both Parties shall make every effort to ensure that such
solicitations can be advanced in a timely manner, including execution of non-disclosure or confidentiality agreements and sharing of necessary information with prospective partners. 

 

	 	5.6.	 Each Party shall, as promptly as reasonably practicable, inform the other Party and regularly report its
business development activities that pertain to this Agreement and the Product to the other Party. Without limiting the generality of the foregoing, representatives from the Parties, including Dr. Javitt and Aaron Gorovitz on behalf of NeuroRx,
will attend the Weekly Calls to report all updates on the Product and the Collaboration to Relief. 

  

	 	5.7.	 Any material licensing, partnership or distribution or other similar agreement proposed by a Third Party entity
with respect to the Product shall be subject to express prior written consent of each Party (such consent not to be unreasonably withheld or delayed). 

  

	 	5.8.	 Each of the Parties shall refrain from, and shall use commercially reasonable efforts to cause its Affiliates
to refrain from, taking any action, or permitting any Person from taking any action that could frustrate the exclusivity provisions set forth above. 

  

	6.	 Invoices and Audit Right 

 

	 	6.1.	 NeuroRx shall, as promptly as reasonably practicable, provide accurate and complete vendor and other service
provider invoices, along with supporting documentation and any other information reasonably requested by Relief, and Relief shall pay such invoices in accordance with the approved budget for the Project and the terms of the applicable vendor or
service provider contract. 

  

	 	6.2.	 Within 15 business days of the effectiveness of this Agreement, NeuroRx shall provide to Relief all invoices,
purchase orders, receipts, contracts (both written as well as a description of the material terms of any oral agreements that are legally binding), and expense documentation for any costs incurred with respect to its Product development activities
through such date. 

  

	 	6.3.	 Relief shall have customary and reasonable rights to access all books and financial records of NeuroRx and its
Affiliates with respect to the Project. 

  

							
	 	 	 	 	 Page  |
	  	7

	 	6.4.	 If and to the extent approved by the applicable Third Party contractors, Relief shall also have customary and
reasonable rights to access relevant records of material Third Party contractors engaged by NeuroRx or any of its Affiliates with respect to the Project, and NeuroRx shall cooperate with Relief with respect to Relief’s obtaining such records.

  

	7.	 Press Releases and Material Information 

 

	 	7.1.	 None of NeuroRx, Relief, any of its respective Affiliates or any Person acting at the direction or on behalf of
NeuroRx, Relief or any of its respective Affiliates, shall issue any press releases or public statements pertaining to the Collaboration, the Project, the Product or any related activities or subject matter without prior express written consent of
the other Party, except as required by applicable laws in which case the issuing Party or Person shall provide the other Party with reasonable prior written notice thereof. All press releases regarding the Product shall be issued in accordance with
all applicable laws. The Parties recognize that press interviews will be given by both Parties, and a set of talking points regarding the Collaboration, the Project, the Product and any related activities or subject matter will be prepared at the
Weekly Calls, approved by NeuroRx and Relief, and provided to each Party. Each Party shall adhere, and shall require its Affiliates and other Third Parties acting on such Party’s or its Affiliates’ behalf to adhere, to such talking points.

  

	 	7.2.	 In part due to the fact that Relief is publicly listed in Switzerland and regulated by the Swiss Stock Exchange
(SIX), NeuroRx commits to coordinate and cooperate with Relief regarding the timely public release of all material information pertaining to the development and commercialization of the Product. Such information will be discussed on the Weekly
Calls, and more frequently as may be necessary to comply with Relief’s obligations. This clause shall be deemed to refer to, but shall not be construed to obligate the release of, scientific or other similar documents, materials, date or
information, before its primary authors consider the foregoing appropriate for public release. 

  

	 	7.3.	 During the Weekly Calls, or more frequently as necessary or reasonably requested by Relief, NeuroRx shall
provide progress reports and status updates to Relief regarding the RLF-100 development program, including ongoing updates regarding all current and planned clinical trials, clinical activity profile of the
Product, technical specifications, stability data, and any other information that pertains to the composition and formulation of the Product in any of its manifestations. Any and all drug-related serious adverse events as defined by the FDA shall be
transmitted by NeuroRx to Relief in a timely manner, and in no event less frequently or later than the Weekly Calls. 

  

	 	7.4.	 NeuroRx shall promptly furnish to Relief, subject to approval, if needed, by applicable licensors in license
agreements to which NeuroRx is licensee, any and all information in its possession, including IND filings owned or licensed by NeuroRx, that is not currently in the public domain pertaining to (i) the clinical activity profile of the Product,
(ii) technical specifications, (iii) stability data, (iv) the composition and formulation of the Product in any of its manifestations, and (v) any financing arrangement that reasonably relates to the Product or Collaboration,
including any such financing with any Prior Funding Source (defined below). 

  

	 	7.5.	 Within three business days of the effective date of this Agreement (or earlier if required by any applicable
law or securities exchange regulations), the Parties shall jointly release an agreed upon press release that indicates what each Party brought to the Collaboration and how the Parties intend to move forward with the Collaboration. In the event that
the Parties are unable to mutually agree on any such joint press release, counsel for each Party shall agree on and appoint a mediator who will decide the issue within 3 days. 

  

							
	 	 	 	 	 Page  |
	  	8

	8.	 Consideration 

 

	 	8.1.	 Relief shall fund the estimated $8.3 million clinical trial budget as approved by Relief’s Board of
Directors on March 22, 2020 and as may be amended by the written agreement of Relief and NeuroRx. It is understood that clinical research budgets are estimates only because one can never know exactly how many patients will be enrolled, what
actual medical costs will be, how many hours will be spent on statistics, report-writing, etc. That being said, any amended budget shall be subject to prior approval by Relief and NeuroRx and shall provide for reasonable cost overruns based on
changes in the regulatory environment and requirements. Budget overages of less than 30% shall be automatically approved. In the event that Relief does not approve additional overages, NeuroRx shall be free to bring in other Persons in order to
complete the Project. 

  

	 	8.2.	 Relief shall fund the costs of formulation and stability of the Product at MediSourceRx and Bachem, together
with technology transfer to Nephron Pharmaceuticals or other mutually agreeable commercial manufacturers. 

  

	 	8.3.	 Relief shall fund the documented costs of purchasing drug substance from Bachem and manufacturing drug product
at MediSourceRx and Nephron Pharmaceuticals. 

  

	 	8.4.	 Relief shall be reimbursed for all costs of goods sold paid for by Relief prior to calculating any Net Profit
sharing by the Parties in any Territory as set forth in this Agreement. 

  

	 	8.5.	 Each Party will develop a Commercialization Plan for the Product for such Party’s respective Territory
mutually agreed upon by the other Party (such agreement not to be unreasonably withheld, conditioned or delayed) within 60 days hereof. In the event that the Parties are unable to mutually agree on any such Commercialization Plan, counsel for each
Party shall jointly appoint an arbitrator who will decide the issue in binding arbitration within 14 days. 

  

	 	8.6.	 If there is a dispute regarding either Party’s Commercialization Plan, the Parties will engage a mutually
agreed arbiter, and any costs with respect to such engagement shall be shared on a 50/50 basis by the Parties. 

  

	 	8.7.	 Each Party will use “commercially reasonable efforts” to commercialize Product in its respective
Territory consistent with its Commercialization Plan. 

  

	 	8.8.	 Each of NeuroRx and Relief can audit the distributor as needed. Final decisions regarding the distribution
partner in the NeuroRx territory shall be made by NeuroRx, and final decisions regarding the distribution partner for the Relief Territory shall be made by Relief. 

 

	 	8.9.	 Each Party will provide access and right of reference to all existing clinical,
non-clinical, and CMC information for the Product that it owns or licenses from a Third Party. 

  

	 	8.10.	 Each Party will have full rights to commercialize the Product in its respective Territory, in each case,
subject to its Commercialization Plan including, e.g., the right to commercialize Product in its respective Territory itself or through any licensees, distributors or other Third Parties and with the right to contract with contract research
organizations, contract marketing organizations and other Third Parties. Each Party agrees not to commercialize the Product in the other Party’s Territory. 

 

	 	8.11.	 The Parties acknowledge that the efficacy of RLF-100 is currently
unknown and the commercial sales model will be driven by the efficacy-driven label together with the available patient population. Entry of vaccines and other therapeutics could dramatically alter the incidence of Critical COVID-19 with Respiratory Failure as can the overall incidence of SARS-CoV-2 infection. For this reason the Parties have agreed to
engage IQVIA to build a commercial sales model based on the Target Product Profile that is informed by interviews with physicians, payers, and hospitals. This model will yield a target price point and potential market penetration. The actual sales
target will be adjusted up or down by changes in the actual infection rate as reported 

  

							
	 	 	 	 	 Page  |
	  	9

	 	
by the CDC. NeuroRx will commit to a standard peak sales penetration model together with Relief, which is typically 20%/40%/60%/80%/100% of forecast peak sales in years 1-5 respectively. Should NeuroRx underperform its target by 30% or more without macroscopic changes in the market environment, Relief shall have the right to demand an outside sales entity be engaged to manage US
sales. 

  

	9.	 Profit Sharing 

 

	 	9.1.	 NeuroRx shall receive 50% of Net Profits and Relief shall receive 50% of Net Profits from the Product sales in
the NeuroRx Territory. NeuroRx shall maintain books and records sufficient to confirm the Net Profits generated from the sales of Product in the NeuroRx Territory consistent with GAAP. Relief will have the right (itself or through an independent
auditor) to audit NeuroRx’s books and records to confirm the Net Profits from NeuroRx’s sales of Product in the NeuroRx Territory. 

  

	 	9.2.	 NeuroRx shall receive 15% of Net Profits and Relief shall receive 85% of Net Profits from the Product sales in
the Relief Territory. Relief shall maintain books and records sufficient to confirm the Net Profits generated from the sales of Product in the Relief Territory consistent with GAAP. NeuroRx shall have the right (itself or through an independent
auditor) to audit Relief’s books and records to confirm the Net Profits from Relief’s sales of Product in the Relief Territory. Should Relief request assistance from NeuroRx in clinical development, manufacture, or commercialization,
NeuroRx shall be entitled to additional consideration as agreed between the Parties. 

  

	 	9.3.	 NeuroRx shall receive 20% of Net Profits and Relief shall receive 80% of Net Profits from the Product sales in
the ROW Countries. Relief shall maintain books and records sufficient to confirm the Net Profits generated from the sales of Product in the ROW Countries consistent with GAAP. NeuroRx shall have the right (itself or through an independent auditor)
to audit Relief’s books and records to confirm the Net Profits from Relief’s sales of Product in the ROW Countries. Should Relief request assistance from NeuroRx in clinical development, manufacture, or commercialization, NeuroRx shall be
entitled to additional consideration as agreed between the Parties. 

  

	10.	 Intellectual Property and Regulatory Approvals 

 

	 	10.1.	 Each Party shall appoint a law firm acceptable to the other to manage the filing of applications and the
prosecution thereof and the ownership (which may not necessarily follow inventorship), protection, maintenance, enforcement, and defense of Patents, trademarks and other IP in their respective Territories and, as applicable, any ROW Countries, other
customary IP provisions, and any other provisions mutually agreed upon by the Parties. Relief agrees that the firm appointed by NeuroRx may be Kirkland & Ellis, LLP. 

 

	 	10.2.	 Following the date hereof NeuroRx and Relief shall disclose to one another all IP owned, licensed, or claimed
by each in order to permit the parties to implement all cross-licensing or other arrangement involving ownership and licensing of IP between the Parties, subject to approval, if needed, by applicable licensors in license agreements.

  

	 	10.3.	 Relief agrees NeuroRx shall be designated as the sole applicant on any NDA or other application for a
Regulatory License submitted to FDA with respect to the Product. The Parties agree that Relief shall jointly control all material decisions related to the NDA or other application for a Regulatory License and related matters and receive half the
economic benefit of all NDAs or other Regulatory Licenses and related IP and commercialization thereof in the United States. 

  

							
	 	 	 	 	 Page  |
	  	10

	 	10.4.	 All IP, including all Patents or Information, that is related to the Collaboration or the Product and
(a) is or was created, developed, invented, made or enhanced by NeuroRx, any of its Affiliates, Dr. Javitt, or any Third Party vendor or service provider for or on behalf of NeuroRx, any of its Affiliates or Dr. Javitt, (b) is
owned or licensed by NeuroRx, any of its Affiliates or Dr. Javitt, or (c) the creation, development, invention, making or enhancement of which was funded in any manner by Relief (all such IP, “Prior IP”) is set forth on
Schedule A hereto. 

  

	 	10.5.	 Each of NeuroRx (on behalf of itself and its Affiliates) and Dr. Javitt shall, and shall use commercially
reasonable efforts to cause each of its respective Affiliates, vendors and service providers, as applicable, to, irrevocably crosslicense to Relief for use in its territory all of their respective right, title and interest in, to and under the Prior
IP (and shall abandon or assign to Relief the US trademark application for “RLF-100” after signing this Agreement), and each of NeuroRx and Dr. Javitt shall take, and shall use commercially
reasonable efforts to cause each of its respective Affiliates, vendors and service providers, as applicable, to take, all necessary actions to obtain, effectuate and perfect such assignments. 

 

	 	10.6.	 Relief (on behalf of itself and its Affiliates) hereby, and shall promptly cause each of its respective
Affiliates, vendors and service providers, as applicable, to, irrevocably crosslicense to NeuroRx for use in its territory all of their respective right, title and interest in, to and under the Prior IP, and Relief shall take, and shall promptly
cause each of its respective Affiliates, vendors and service providers, as applicable, to take, all necessary actions to obtain, effectuate and perfect such assignments. 

 

	 	10.7.	 Intellectual Property that is developed jointly by the Parties relating to the Product during the term of this
Agreement will be owned jointly by the Parties in accordance with US patent law (“Joint IP”). To be considered Joint IP, the subject Intellectual Property shall be invented by at least one employee, contractor or agent of each Party (each,
a “Party Inventor”) working collaboratively with one another regardless of the location(s) in which the respective Party Inventors conduct the inventive activities that contribute to the invention of the Joint IP. Relief will assign to
NeuroRx its rights in such Joint IP in the NeuroRx Territory, and NeuroRx will assign to Relief its rights in such Joint IP in the Relief Territory. The Parties will ensure that the rights to Joint IP necessary to ensure freedom to operate for each
Party in the ROW Countries are cross-licensed in the license grants contemplated in this Section 10. 

  

	 	10.8.	 All publications and manuscripts, whether published or submitted or proposed for publication, related to the
Product and authored by Dr. Javitt or any employee, consultant or contractor of NeuroRx, any of its Affiliates or Dr. Javitt as of the effective date of this Agreement (“Prior Publications”) are set forth on Schedule B
hereto. 

  

	 	10.9.	 All sources, aside from Relief, that have provided or agreed to provide any capital, funding, grants, or
financial support in any form to Dr. Javitt or NeuroRx to be used in connection with, or to in any manner further, the Collaboration or any element thereof., and the amounts provided, as of the effective date of this Agreement (“Prior
Funding Sources”) are set forth on Schedule C hereto. Prior to the date hereof, NeuroRx has provided Relief with all documentation related to any financing or other related matters with each Prior Funding Source. 

 

	11.	 Representations and Warranties 

Each of the Parties hereby represents and warrants to the other Party, as of the date hereof, as follows: 

 

	 	•	 	 Such Party is duly organized or incorporated (as the case may be), validly existing and in good standing under
the jurisdiction of its incorporation or organization, has all requisite power and authority to carry on its business as now conducted, has full power and authority to enter into this Agreement, consummate the transactions contemplated hereby and to
perform its obligations hereunder. 

  

							
	 	 	 	 	 Page  |
	  	11

	 	•	 	 The execution, delivery and performance by such Party and the consummation of the transactions contemplated
hereby: 

  

	 	•	 	 (a) have been duly and validly authorized and approved by the board of directors of such Party, and no other
corporate actions or proceedings on the part thereof is necessary to authorize this Agreement and the transactions contemplated hereby; 

  

	 	•	 	 (b) to the best of such Party’s knowledge, do not and will not result in the creation or imposition of
any liens with respect to any of the material assets or properties of such Party; and 

  

	 	•	 	 (c) to the best of such Party’s knowledge, do not and will not result in a violation or breach of or
conflict with (i) such Party’s articles, bylaws, or other organizational documents, (ii) any law, rule, regulation or order to which such Party is subject, or (iii) any judgment, order, or decree of any governmental authority to
which such Party is subject, or otherwise result in a violation or breach of or conflict with, or constitute a default under, or result in the acceleration of any material provision of, any contract or agreement to which such Party is bound.

  

	 	•	 	 The provisions set forth in this Agreement constitute legal, valid and binding obligations of such Party
enforceable against such Party in accordance with their respective terms, except to the extent that enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting the enforcement of creditors’ rights generally and
subject to general principles of equity (regardless of whether such enforcement is considered in a proceeding at law or at equity), public policy or national security. 

 

	 	•	 	 Such Party is in material compliance with all applicable laws, regulations, rules and orders and there is no
basis that, with or without notice or the passage of time (or both), would, individually or in the aggregate, be reasonably expected to constitute or give rise to a violation of, any applicable law, regulation, rule or order. 

 

	 	•	 	 There are no actions pending against or affecting such Party’s ability to enter into or complete its
obligations under this Agreement. 

  

	 	•	 	 Neither this Agreement (including the Schedules hereto) nor any other documents, certificates or instruments
furnished by a Party to the other Party its Affiliates in connection with the Collaboration contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made herein or therein, in the
light of the circumstances under which they were made herein or therein, not misleading. 

  

	 	•	 	 Notwithstanding the foregoing, each Party, on its own behalf and on behalf of its respective Affiliates,
acknowledges and agrees that (a) such Party’s representations and warranties set forth herein constitute the sole and exclusive representations and warranties of such Party in connection with the Agreement and the transactions contemplated
hereunder; (ii) neither such Party, nor any of its representatives or Affiliates, nor any other Person makes, or has made, any other express or implied representation or warranty with respect to the Agreement or the transactions contemplated
hereunder; and (iii) each Party is relying solely upon the other Party’s representations and warranties hereunder and are not relying, and have not relied, upon any other information, document or material provided to or made available to
such Party, or any of its representatives or Affiliates (including the completeness or accuracy thereof), whether oral or written, delivered to or made available prior to or after the date hereof. 

  

							
	 	 	 	 	 Page  |
	  	12

 Other Terms 
  

	 	12.1.	 The Parties recognize that the Product – a form of vasoactive intestinal peptide (VIP) – is a generic
product, sold by multiple drug substance suppliers in multiple countries, and is currently listed in the FDA “Bulks” list for sale by any compounding pharmacy. The Parties further recognize that: 

 

	 	•	 	 Relief owns U.S. Patent No. 8,178,489 and related patents derived from U.S. Patent Appl. Serial
No. 11/817,867 and its international counterparts that cover certain formulations of the Product but does not cover either its use or composition of matter; 

 

	 	•	 	 it would be in their mutual interest for Relief to obtain additional IP and a patent term extension related to
the Product; 

  

	 	•	 	 Relief has certain Information that may be useful in commercializing the Product; and 

 

	 	•	 	 NeuroRx has Information, included or embodied in United States IND 149,152, 151,070 and related documents filed
with the FDA. 

  

	 	12.2.	 NeuroRx’s Commercialization Plan for the NeuroRx Territory shall (i) include a branding plan, sales
team information, pricing and market research, documentation of advanced purchase orders, forward contracts, bulk supply arrangements, distribution arrangements, and other topics customary for the commercialization of a pharmaceutical product in the
United States. NeuroRx will choose a name, with Relief’s consultation that meets FDA approval. For the avoidance of doubt, Relief shall have sole right to identify commercialization partners everywhere in the world other than the NeuroRx
Territory, which shall be subject to the terms of this Agreement. Both Relief and NeuroRx agree that this process shall be mediated by a Person with recognized expertise in pharmaceutical industry asset licensing or acquisition.

  

	 	12.3.	 If either Relief or NeuroRx wants to expand the Product franchise outside the scope of the Collaboration in its
respective Territory, it shall be entitled to keep 100% of the Revenues. Neither party may expand into the other’s Territory without the other’s permission. 

 

	 	12.4.	 NeuroRx and Relief shall each maintain clinical trials insurance that covers all subjects enrolled in clinical
development activities conducted by the respective Party. 

  

	 	12.5.	 Relief agrees that it shall fund the costs associated with the clinical development of the inhaled Product in
the United States in reliance upon NeuroRx’s agreement to conduct, manage, supervise and oversee said clinical development. Should Relief not fund the clinical development costs, NeuroRx shall have the freedom to bring a replacement investor.

  

	 	12.6.	 The Parties will form a JSC to coordinate the activities between the Parties with regard to each Party’s
respective Territory. The JSC shall not have governing authority, and will be limited to an advisory capacity and will not have any governing or decision-making authority. The main role of the JSC is to ensure that neither Party undertakes
regulatory actions that could adversely affect the other Party (e.g., failure to report adverse events and other issues that arise in the Parties’ respective Territories that would reasonably be likely to impact the other Party or the Product.
For clarity, each Party will have the right to have final say with regard to its own respective Territory. 

  

							
	 	 	 	 	 Page  |
	  	13

	13.	 Choice of Law, Venue, Dispute Resolution, and Miscellaneous 

 

	 	13.1.	 Any disputes arising from this Agreement shall be addressed first by escalating to senior executives of each
Party for resolution over the course of a period of 30 days (or another mutually agreed period of time) except with regards to disputes over alleged or possible violations of law or public policy or involving matters of national security.

 This Agreement and all questions regarding its validity or interpretation, or the performance or breach of this
Agreement, shall be governed by and construed and enforced in accordance with the laws of New York, without reference to conflicts of laws principles. Venue shall be in the courts of New York. Each Party hereby irrevocably submits to the exclusive
jurisdiction of the courts of New York. 
  

	 	13.2.	 The section headings in this Agreement are included only for convenience of reference and shall not in any way
affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement: (a) the word “including” shall be deemed to be followed by the phrase “without limitation” or like expression;
(b) the words “Subject to further discussion between the Parties”, “mutually agreed to by the Parties” or words of other similar import, shall each be deemed to be followed by the phrase “each of the Parties acting
reasonably and in good faith, consistent with the principles set forth in this Agreement”, (c) the word “commercialization” shall be deemed to also reflect the words “or other monetization”, (d) references to the singular
shall include the plural and vice versa; (e) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; and (f) the words “herein” or “hereunder” relate to this Agreement. If any
term or other provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other terms, provisions and conditions of this Agreement
shall nevertheless remain in full force and effect. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the
original intent of the Parties as closely as possible to the fullest extent permitted by applicable law in an acceptable manner to the end that the Collaboration is fulfilled to the extent possible. 

 

	 	13.3.	 This Agreement will be publicly disclosed by the parties as required by law, with the prior written consent of
the parties. Specifically, this Agreement may be disclosed (a) to potential future investors who sign a nondisclosure agreement and (b) if required in connection with NeuroRx going public or merging with a public company and in connection
with required public filings of Relief. The Parties agree that this Agreement constitutes a binding legal obligation of the Parties; provided that if the Parties fail to receive any approvals, clearances or other permission necessary to proceed with
respect to the Collaboration contemplated herein, the Parties will make the necessary amendments hereto to obtain approvals. 

  

	 	13.4.	 No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of
an amendment, by both Parties; or, in the case of a waiver, by the Party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be
a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either Party to exercise any right hereunder in any manner impair the exercise of any such right accruing to it
thereafter. This Agreement contains the entire agreement between the Parties with respect to the subject matter hereof, and supersedes any and all prior understandings or agreements, whether written or oral, and there no promises, agreements,
conditions, undertakings, warranties, or representations (whether oral or written, express or implied) between them other than as herein set forth. Neither Party shall assign or transfer this Agreement or any of its rights or obligations hereunder,
in whole or in part, without the prior 

  

							
	 	 	 	 	 Page  |
	  	14

	 	
written consent of the other Party; provided that either Party may assign or transfer this Agreement or any or all of its rights or obligations under this Agreement from time to time without
consent: (a) to an Affiliate; or (b) to an acquirer of all or substantially all of such Party’s business, equity or assets. This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and
permitted assigns. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. There are no third party beneficiaries to this Agreement and
nothing contained in this Agreement is intended to or shall be interpreted to create any third party beneficiary claims. Each of the Parties hereto has jointly participated in the negotiation and drafting of this Agreement. In the event an ambiguity
or a question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by each of the Parties hereto and no presumptions or burdens of proof shall arise favoring any Party by virtue of the authorship of any
provisions of this Agreement. 

  

	 	13.5.	 Each Party represents to the other that (i) it is not aware of any facts which would give rise to a cause
of action related to the prior activities between the Parties and the COVID-19 drug, and (ii) it has no claims against the other based on facts which are known. 

 

	 	13.6.	 Any costs with respect to binding arbitration or mediation shall be shared on a 50/50 basis by the Parties.

 [signature page follows] 

  

							
	 	 	 	 	 Page  |
	  	15

			
	Acknowledged and Agreed:
	
	 /s/ Raghuram Selvaraju

	Relief Therapeutics Holding AG
	By:	 	 Raghuram Selvaraju, Ph.D.
 Chairman of the
Board

  

			
	 /s/ Peter de Svastich

	 Therametrics Discovery AG

	By:	 	Peter de Svastich
	Director

  

			
	 /s/ Jonathan C. Javitt

	NeuroRx, Inc.
	By:	 	Jonathan C. Javitt, M.D., M.P.H.
		 	Chairman and CEO
		
	Date:	 	September 18, 2020

  

							
	 	 	 	 	 Page  |
	  	16

 SCHEDULE A – PRIOR IP 

US Trademark Application No. 88875871, “SAMIVIP”, filed April 17, 2020 

US Trademark Application No. 90087709, “SAMIVIR”, filed August 2, 2020 

US Trademark Application No. 90110838, “RLF-100”, filed August 13, 2020 

US Trademark Application No. 90179858, “SAMIAIR”, filed September 14, 2020 

US Provisional Patent Application entitled “Compositions and Methods for Treating COPD and Other Pulmonary Disorders Using Vasoactive Intestinal
Peptide” (currently in draft) 
 US Provisional Patent Application entitled “Compositions and Methods for Improving Quality of Life in Critical
Care Patients Using Vasoactive Intestinal Peptide” (currently in draft) 
 US Provisional Patent Application entitled “Direct Central Nervous
System Delivery of Vasoactive Intestinal Peptide for Treatment and Prevention of Neurological Disorders” (currently in draft) 
 Know-how relating to formulation, storage and intravenous delivery of Vasoactive Intestinal Peptide (aviptadil) 
 Know-how relating to formulation, storage and inhalation delivery of Vasoactive Intestinal Peptide (aviptadil) 

 SCHEDULE B – PRIOR PUBLICATIONS 

 

	1.	 Youssef, Jihad G. and Al-Saadi, Mukthar and Zahiruddin, Faisal and
Beshay, Sarah and Bitar, Mohammad and Javitt, Jonathan, Rapid Recovery from COVID-19 Respiratory Failure with Comorbidity in 21 Patients Treated with Vasoactive Intestinal Peptide. THELANCET-D-20-16032, Available at SSRN: https://ssrn.com/abstract=3679909 

 

	2.	 Javitt, Jonathan and Youssef, Jihad G., VIP: A COVID-19 Therapeutic
that Blocks Coronavirus Replication (August 9, 2020). Available at SSRN: https://ssrn.com/abstract=3670129 

  

	3.	 Youssef, Jihad G. and Said, Sami and Youssef, George and Javitt, Matthew J. and Javitt, Jonathan, Treatment of
Sepsis-related Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide (July 29, 2020). Available at SSRN: https://ssrn.com/abstract=3662952 or http://dx.doi.org/10.2139/ssrn.3662952 

Note: These publications may be elsewhere on the internet in earlier forms 

 SCHEDULE C – PRIOR FUNDING SOURCES 

NeuroRx, Inc. 

 BOARD RESOLUTION 

APPROVING AGREEMENT 
 The undersigned, as
Directors of Relief Therapeutics Holding Aktiengesellschaft and its wholly owned subsidiary Therametrics Discovery Aktiengesellschaft (collectively, the “Company”), hereby attest that the following resolution was adopted by the Board of
Directors of the Company in accordance with applicable law: 
 RESOLVED, that the Collaboration Agreement presented to the Board of Directors in the form of
Exhibit A hereto is hereby approved, and the officers of the Company are, and each individually is, authorized and instructed, for and in the name of the Company to execute and deliver such Agreement in substantially the form that was presented to
the Board of Directors as contained in Exhibit A, with such changes thereto as the person executing the same shall approve, such approval to be conclusively evidenced by the execution and delivery thereof. 

RESOLVED, that the Directors of this Company are, and each acting alone is, hereby authorized to do and perform any and all such acts, including execution of
any and all documents and certificates, as such Directors shall deem necessary or advisable, to carry out the purposes and intent of the foregoing resolutions. 

RESOLVED FURTHER, that any once executed by Ram Selvaraju and Peter de Svastich, the Collaboration Agreement shall become a legally binding and enforceable
obligation of the Company in accordance with its terms. 
  

	
	 /s/ Ram Selvaraju

	Ram Selvaraju, Director

  

	
	 /s/ Peter de Svastich

	Peter de Svastich, DirectorEX-10.32

 Exhibit 10.32 

[Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with
asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.] 

EXCLUSIVE DISTRIBUTION AGREEMENT 
 This
Exclusive Distribution Agreement (the “Agreement”) is made as of this 25th day of September 2020 (the “Effective Date”), between NeuroRx, Inc., a Delaware
corporation, with a principal mailing address of 913 North Market Street, Suite 200, Wilmington, Delaware 19801 (“Client”), and Cardinal Health 105, Inc., an Ohio corporation, with a place of business at 501 Mason Road, Suite 200,
La Vergne, Tennessee, 37086 (“Cardinal Health”) each individually a (“Party”) and collectively (the “Parties”). 

RECITALS 

A.    Client is, among other things, in the business of developing and marketing pharmaceutical products in the United
States, its territories, possessions and commonwealths (“Territory”). 
 B.    Cardinal Health is,
among other things, in the business of distributing pharmaceutical products to wholesalers, specialty distributors, physicians, clinics, hospitals, pharmacies, and other health care providers in the Territory, and of providing information systems
and other services that support its clients’ use of its distribution capabilities. 
 C.    Client desires to
engage Cardinal Health as its exclusive third-party logistics distribution agent for commercial sales of all pharmaceutical Products manufactured and/or marketed by Client in all formulations (collectively, “Product”), and to
perform certain other services described in this Agreement, all upon the terms and conditions set forth in this Agreement. 
 THEREFORE,
in consideration of the mutual covenants, terms and conditions set forth below, the Parties agree as follows: 
 ARTICLE 1 

APPOINTMENT/AUTHORIZATION 

1.1    Appointment. Subject to the terms and conditions set forth in this Agreement, during the term of this Agreement, Client
appoints Cardinal Health as its exclusive third-party logistics distribution agent and as an authorized distributor of record of Product in the Territory to Client’s Customers, including, but not limited to, wholesalers, specialty distributors,
physicians, clinics, hospitals, pharmacies and other health care providers in the Territory (collectively, “Customers”). 

1.2    Acceptance of Appointment. Subject to the terms and conditions set forth in this Agreement, Cardinal Health accepts the
appointment to represent Client as its exclusive third-party logistics distribution agent and as an authorized distributor of record of Product to Customers in the Territory. 

  
 1 

 ARTICLE 2 

SERVICES 

2.1    Services. Cardinal Health shall provide the services set forth in the Traditional 3PL Operating Guidelines
(“OPG”) and/or the Title Model Operating Guidelines (“TMOPG”), whichever is applicable and include, without limitation, storage, distribution, returns, customer support, financial support, EDI and system access
support (“Services”). The OPG shall be finalized and mutually agreed upon prior to the commercial launch of Product. Once finalized, a copy of the OPG shall be attached hereto as Exhibit A and a copy of the TMOPG shall be
attached to the Title Model Addendum as Attachment 1, and each shall be incorporated by reference. 
 2.2    Traditional 3PL
Operating Guidelines and Title Model Operating Guidelines. The OPG and TMOPG may be amended from time to time upon the mutual written agreement of the Parties; provided, however, that any change, modification or amendment to the OPG and/or TMOPG
may result in an increase in the Fees (as defined in Article 5). 
 2.3    Compliance to Traditional 3PL Operating Guidelines.
Cardinal Health’s services shall comply with the OPG and/or TMOPG for up to 125% of Client’s Forecast (defined below). If (i) Client’s shipments of Product to Cardinal Health or (ii) Client’s Customers’ Product
orders exceed Client’s Forecast by more than twenty-five percent (25%), Cardinal Health shall use commercially reasonable efforts to meet the requirements of the OPG and/or TMOPG, provided however, that Client acknowledges that in such
situations Cardinal Health may not be able to meet all guidelines relating to response and shipping times. 
 2.4    Product
Returns. All Product returns shall be processed and handled by Cardinal Health in accordance with the OPG and/or TMOPG; and any customization or additional return services requested by Client shall be performed at an additional fee as agreed by
the Parties. 
 2.5    Product Recalls. Client is solely responsible for all Product recalls, provided however that Cardinal
Health shall be responsible for Product recalls to the extent arising from Cardinal Health’s gross negligence or willful misconduct, subject to the terms of this Agreement. In the event Product is subject to recall, or Client, on its own
initiative, recalls any Product, Cardinal Health shall provide assistance to Client as set forth in the OPG and/or TMOPG and as mutually agreed upon, provided that Client shall pay to Cardinal Health an amount equal to Cardinal Health’s actual
costs incurred with any such recall services. Such cost shall be in addition to the Fees described in Article 5 below. 
 ARTICLE 3

 PRODUCT SUPPLY/CLIENT RESPONSIBILITIES 

3.1    Facility. Client shall deliver, or shall have delivered, Product to Cardinal Health at Cardinal Health’s facility
located at 15 Ingram Boulevard, La Vergne, Tennessee 37086 and/or 501 Mason Road, Suite 200, La Vergne, Tennessee 37086, or to such other distribution facility as may be designated by Cardinal Health to Client in writing (“3PL
Facility’’). 

  
 2 

 3.2    Delivery and Title. Client shall be responsible for delivery of Product to
and from the 3PL Facility, including all costs, expenses and risk of loss associated with such delivery. Title to Product shall remain with Client at all times, even when Product is stored or warehoused at the 3PL Facility. Client shall at all times
insure the Product for damage, loss, destruction, theft or any such other property damage (“Loss”) as further set forth in Article 13 below. Except for Loss resulting solely from the gross negligence or willful misconduct of
Cardinal Health, Client shall bear all risk of loss or damage with respect to the Product. 
 3.3    Forecast and Price List.

 A.    Forecast. Client shall provide Cardinal Health with a forecast of the volume of Product to be handled by
Cardinal Health under this Agreement, not less often than semi-annually (“Forecast”). All forecasts, including the Forecast, are used for the express purpose of operational planning. In the event of a significant variance from the
Forecast or a change in core business that could reasonably be expected to have a material effect upon the obligations of either Party hereunder, the Party so affected may notify the other Party that it wishes to negotiate an appropriate adjustment
to the Fees. The Parties must meet within thirty (30) days of such notification to discuss the merits and implementation of any such adjustment and during such meeting, the Parties shall negotiate in good faith. If the Parties are unable to
come to a resolution regarding any such adjustment, the Party originally proposing the adjustment may terminate this Agreement upon one hundred eighty days (180) prior written notice to the other Party. 

B.    Price List. Upon execution of this Agreement, Client shall deliver to Cardinal Health a customer list, which
sets forth the Product prices (the “Customer Price List”). Client shall notify Cardinal Health of any change in the Customer Price List not less than seventy-two (72) hours prior to the
effective date of any such change. Cardinal Health shall use commercially reasonably efforts to implement such price change in accordance with Client’s instruction. 

3.4    Shipment Inspection. Cardinal Health shall visually inspect each shipment of Product for external damage or loss in transit
and notify Client of any such evident damage or loss as provided in the OPG and/or TMOPG. 
 ARTICLE 4 

INFORMATION SYSTEM ACCESS 

4.1    Access. During the Term of this Agreement and subject to the terms herein, Client may use password(s) and identification
number(s) provided by Cardinal Health to remotely access Client’s data maintained on Cardinal Health’s web enabled Operating System Base and certain support services associated therewith, as further set forth in the OPG and/or TMOPG
(collectively, the “System”) provided that such access is used solely by Client’s employees and for Client’s own internal business purposes. Client shall use that access solely to access Client’s data and shall not
access or attempt to access any other data, systems or software. Client shall be responsible for all use of the passwords and identification elements and shall ensure that they are used solely to effect the limited access authorized herein. The
limited license to access the System granted herein does not include the right to copy, download or otherwise use any software or non-Client data maintained on the System. 

  
 3 

 4.2    Fees. The System shall be made available to Client at the fees set forth
in the Fee Schedule. If Cardinal Health agrees to perform any custom enhancements to the System requested by Client, such customization services shall be billed separately based on an hourly rate set forth in the Fee Schedule (as defined in Article
5) and prior to such performance, Cardinal Health shall notify Client of any related increase in the periodic Fees hereunder relative to the ongoing support of the customizations. 

4.3    Security. During the term of this Agreement, Cardinal Health shall employ reasonable security measures and policies designed
to safeguard the integrity, accessibility, and confidentiality of Client’s data resident on the System and establish and maintain reasonable disaster and emergency recovery plans designed to minimize disruption from System operation
interruptions. Such measures shall be no less secure than those utilized by Cardinal Health to protect its own confidential information. 

4.4    Client Obligations. Client shall not reverse engineer, reverse assemble, decompile, create derivative works, modify, or
otherwise attempt to derive the source code of any software on the System or copy, download, modify, or create derivative works of such software. Also, Client shall not permit access to the System or related documentation to any other person or
entity. The System and all parts thereof, in all of their tangible and intangible manifestations, all existing or new enhancements, developments, derivative works, and other modifications to the System (or any part thereof), and all related
proprietary rights, are and shall remain the exclusive property of Cardinal Health. 
 4.5    Disclaimer. THE SYSTEM, THE
SOFTWARE THEREON AND ANY RESULTS OBTAINED THEREFROM ARE PROVIDED ON AN “AS IS” BASIS, WITHOUT WARRANTY OF ANY KIND, WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE. EXCEPT AS OTHERWISE PROVIDED HEREIN AND/OR TO THE EXTENT PERMITTED BY
LAW, CARDINAL HEALTH MAKES NO REPRESENTATIONS OR WARRANTIES, AND HEREBY EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, RELATING DIRECTLY OR INDIRECTLY TO THE SYSTEM OR ANY PART THEREOF INCLUDING WITHOUT LIMITATION
WARRANTIES OF MERCHANTABILITY, NONINFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE. 
 4.6    System Availability. Cardinal
Health shall use reasonable efforts to make the System available for access twenty-four (24) hours a day, seven (7) days a week absent scheduled and emergency maintenance periods. 

4.7    Suspension of Access. Notwithstanding anything to the contrary, in the event of a breach of any term of this Agreement or a
threatened breach of the System, Cardinal Health may revoke or suspend any or all passwords and identification numbers provided to Client hereunder. 

  
 4 

 ARTICLE 5 

PRICING AND PAYMENT TERMS 

5.1    Fees. As compensation for the Services, Client shall pay to Cardinal Health the fees (“Fees”) set forth on
Exhibit B (“Fee Schedule”) attached hereto and incorporated by reference. 
 5.2    Invoices. Cardinal
Health shall issue an invoice to Client for the Services rendered under this Agreement or for any other amounts due on a monthly basis. Payment is due within thirty (30) days of the invoice date via electronic funds transfer (EFT) or Automated
Clearing House (ACH). If the invoice is not paid within such thirty (30) day period, Cardinal Health may, at its option elect to (i) impose a service charge on the unpaid amount calculated at the rate of 1.5% per month (or the maximum rate
permitted by law if such rate is less than 1.5% per month) until such amount is paid in full and/or (ii) suspend any further Services until such invoice is paid in full. 

5.3    Fee Adjustment. 

A.    The Fees shall be held firm for the first contract year. Thereafter, Cardinal Health will evaluate the fee schedule
and may adjust the Fees not more often than once per contract year by three percent (3%). 
 B.    Notwithstanding the
terms set forth above in Section 5.3(A), if Cardinal Health can reasonably demonstrate that the costs for providing the Services have materially increased, or are likely to materially increase in the coming year due to the adoption of any
applicable law or regulation (or any material change in the interpretation or administration thereof), or due to unforeseen circumstances beyond Cardinal Health’s reasonable control, then upon notice from Cardinal Health, the Parties agree to
meet in good faith and negotiate a mutually acceptable adjustment to the Fees. 
 5.4    Taxes. Client shall pay when due all
sales, use, gross receipts, excise and personal property taxes associated with the Product (excluding any personal property tax associated with Cardinal Health’s equipment used in connection with the Services), and other taxes now or hereafter
imposed as a result of the transactions contemplated by this Agreement, none of which have been included in the fees payable to Cardinal Health under this Agreement; provided that the amounts payable by Client under this section shall not include
taxes based on the net income of Cardinal Health. 
 ARTICLE 6 

TERM AND TERMINATION 

6.1    Term. The Initial Term of this Agreement shall begin on the Effective Date and shall continue for a period of three
(3) years following the first shipment of FDA-approved Product to a commercial customer (“Initial Term”), unless terminated earlier pursuant to this Agreement. Thereafter, this Agreement
shall automatically renew for additional terms of one (1) year each (each, a “Renewal Term,” and together with the Initial Term, the “Term”), unless written notice of termination is given by either Party at
least ninety (90) days prior to the end of the Initial Term or any Renewal Term. 

  
 5 

 6.2    Termination. Either Party shall have the right to immediately terminate
this Agreement if: 
 (A)    the other Party files a petition in bankruptcy, or enters into an agreement with its
creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or suffers or permits the entry of any order adjudicating it to be bankrupt or insolvent and such order is not
discharged within thirty (30) days; or 
 (B)    the other Party materially breaches any of the provisions of this
Agreement, and such breach is not cured within thirty (30) days after the giving of written notice; provided, however, that (i) in the case of a breach that cannot be cured within thirty (30) days, the Parties agree to meet in good
faith and within thirty (30) days after the giving of written notice, formulate a mutually agreeable plan to cure such breach within a reasonable period of time; and (ii) in the case of a failure of Client to make payments in accordance
with the terms of this Agreement, Cardinal Health may terminate this Agreement if such payment breach is not cured within fifteen (15) days following Cardinal Health’s delivery of a written notice of
non-payment to Client. 
 6.3    Effect of Termination. Expiration or termination of this
Agreement shall be without prejudice to any rights or obligations that accrued to the benefit of either Party prior to such expiration or termination. Client shall pay Cardinal Health for all Services performed up to the date of termination and
shall reimburse Cardinal Health for all costs and expenses incurred, and all non-cancelable commitments made, in the performance of Services. Upon termination or expiration of this Agreement, all Product shall
be returned to Client or a designee of Client, at Client’s sole cost and expense. 
 ARTICLE 7 

REGULATORY 

7.1    Audits. No more than once per calendar year, Client or its designee has the right during normal business hours [i.e., 8:00
a.m. to 5:00 p.m. local 3PL Facility time and not to exceed a total of eight (8) business hours], to conduct a complete quality audit upon thirty (30) business days prior written notice to Cardinal Health. If the timing of such audit falls
during “quarter-end” or “year-end” then Cardinal Health will use best efforts to accommodate Client’s request. Client shall have the right to
conduct for cause audits immediately if necessary, to ensure Product safety or if otherwise necessary to implement or support a Product recall. 

7.2    Compliance with Laws. Each Party shall conduct its activities in connection with this Agreement in compliance with all
applicable United States laws, ordinances, rules, regulations and guidelines. 

  
 6 

 ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1    Cardinal Health. Cardinal Health represents and warrants to Client that, unless otherwise agreed to by the Parties, Cardinal
Health shall perform Services in a workmanlike manner, in accordance with this Agreement, the OPG and/or TMOPG, and applicable United States laws, ordinances, rules, regulations and guidelines. 

8.2    Client. Client represents, warrants and covenants to Cardinal Health that: 

A.    Product. The Product shall not be adulterated or misbranded as provided in the Food, Drug and Cosmetic Act,
as amended from time to time; 
 B.    Promotion. Client’s activities relating to the promotion, sale and
distribution of the Product shall comply with all applicable laws, rules, regulations and guidelines; 
 C.    No
Infringement. It has all necessary authority and right, title and interest in and to any intellectual property related to each Product or that is otherwise provided by Client under this Agreement; 

D.    Safe Handling Instructions. It has provided all safe handling instruction, health and environmental
information and material safety data sheets applicable to the Product or to any materials supplied by Client in writing in sufficient time for review and training by Cardinal Health prior to delivery; and 

8.3    Mutual. Each Party represents and warrants to the other Party that: 

A.    Existence and Power. Such Party (i) is duly organized, validly existing and in good standing under the
laws of the state in which it is organized, (ii) has the power and authority and the legal right to own and operate its property and assets, and to carry on its business as it is now being conducted, and (iii) is in compliance with all
requirements of applicable laws, except to the extent that any noncompliance would not materially adversely affect such Party’s ability to perform its obligations under the Agreement; 

B.    Authorization and Enforcement of Obligations. Such Party (i) has the power and authority and the legal
right to enter into this Agreement and to perform its obligations hereunder and (ii) has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 

C.    Execution and Delivery. This Agreement has been duly executed by an authorized individual and delivered on
behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms; 

D.    No Consents. All necessary consents, approvals and authorizations of all regulatory authorities and other
persons required to be obtained by such Party in connection with the Agreement have been obtained; and 

  
 7 

 E.    No Conflict. The execution and delivery of this Agreement
and the performance of such Party’s obligations hereunder (i) do not conflict with or violate any requirement of applicable laws; and (ii) do not materially conflict with or constitute a material default or require any consent under,
any contractual obligation of such Party. 
 8.4    Limitations. THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE 8
ARE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE BY EACH PARTY TO THE OTHER AND NEITHER PARTY MAKES ANY OTHER REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF
MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. 
 ARTICLE 9 

TRADEMARKS 
 Neither Party shall have the
right to use the name of the other Party or any Affiliate of the other Party, or the other Party’s or such Affiliates’ trademarks, service marks, logos, or other similar marks in any manner except with the prior written approval of that
Party; provided that the foregoing shall not prohibit Cardinal Health’s use of Client’s names or marks in connection with the performance of the Services in a manner consistent with this Agreement. “Affiliate,” as used in
this Agreement, means any legal entity which, during the Term hereof, controls, is controlled by, or is under common control with, such Party. For purposes of this definition, an entity shall be deemed to control another entity if it owns or
controls, directly or indirectly, at least fifty percent (50%) of the voting interest of all equity interests of the other entity (or other such comparable ownership interest for an entity other than a corporation). 

ARTICLE 10 

CONFIDENTIALITY AND NON-USE 

10.1    Mutual Obligation. Cardinal Health and Client agree that they shall not use the other Party’s Confidential Information
(defined below) except as necessary for the receiving Party to perform its obligations under this Agreement or disclose the other Party’s Confidential Information to any third party without the prior written consent of the other Party except as
required by law, regulation or court or administrative order; provided, however, that prior to making any such legally required disclosure, the Party making such disclosure shall give the other Party as much prior notice of the requirement for and
contents of such disclosure as is practicable under the circumstances. Notwithstanding the foregoing, each Party may disclose the other Party’s Confidential Information to any of its Affiliates that (A) need to know such Confidential
Information for the purpose of performing under this Agreement, (B) arc advised of the contents of this article, and (C) agree to be bound by the terms of this article. 

10.2    Definition. As used in this Agreement, the term “Confidential Information” includes all such information
furnished by Cardinal Health or Client, or any of their respective representatives or Affiliates, to the other Party or its representatives or Affiliates in connection with the services or performance of this Agreement, whether furnished before, on
or after the 

  
 8 

 
date of this Agreement and furnished in any form, including but not limited to written, verbal, visual, electronic or in any other media or manner. Confidential Information includes all
proprietary technologies, know-how, trade secrets, discoveries, inventions and any other intellectual property (whether or not patented), analyses, compilations, business or technical information and other
materials prepared by either Party, or any of their respective representatives, containing or based in whole or in part on any such information furnished by the other Party or its representatives. Confidential Information also includes the existence
of this Agreement and its terms. 
 10.3    Exclusions. Notwithstanding Section 10.2, Confidential Information does not
include information that (A) is or becomes generally available to the public other than as a result of a breach of this Agreement, or (B) is already known by the receiving Party at the time of disclosure as evidenced by the receiving
Party’s contemporaneous written records, or (C) becomes available to the receiving Party on a non-confidential basis from a source that is entitled to disclose it on a
non-confidential basis, or (D) was or is independently developed by or for the receiving Party without reference to the disclosing Party’s Confidential Information, as evidenced by the receiving
Party’s written records. 
 10.4    No Implied License. The receiving Party shall obtain no right of any kind or license to
any Confidential Information, patent application, patent, trade secret, know-how or other intellectual property by reason of this Agreement. All Confidential Information shall remain the sole property of the
Party disclosing such information or data. 
 10.5    Return of Confidential Information. Upon termination of this Agreement, the
receiving Party shall, upon request, promptly return within thirty (30) days all such information, including any copies thereof, and cease its use or, at the request of the disclosing Party, shall promptly destroy the same and certify such
destruction to the disclosing Party; except for a single copy thereof, which may be retained for the sole purpose of determining the scope of the obligations incurred under this Agreement. 

10.6    Survival. The Parties intend for this Article 10 to supersede that certain Confidentiality Agreement between the parties
dated the 27th day of July, 2020. The obligations of this Article 10 shall terminate five (5) years from the expiration of this Agreement. 

ARTICLE 11 

INDEMNIFICATION 

11.1    Indemnification by Cardinal Health. Cardinal Health shall indemnify and hold harmless Client, its Affiliates, and their
respective directors, officers, employees and agents (“Client Indemnitees”) from and against any and all suits, claims, losses, demands, liabilities, damages, costs and expenses (including reasonable attorney’ fees) in
connection with any suit, demand or action by any third party (“Liabilities”) arising out of or resulting from (A) any breach of its representations, warranties or obligations set forth in this Agreement or (B) any
negligence or willful misconduct by Cardinal Health, except to the extent that any of the foregoing arises out of or results from any Client Indemnitee’s negligence, willful misconduct or breach of this Agreement. 

  
 9 

 11.2    Indemnification by Client. Client shall indemnify and hold harmless
Cardinal Health, its Affiliates, and their respective directors, officers, employees and agents (“Cardinal Health Indemnitees”) from and against all Liabilities arising out of or resulting from (A) any breach of
its representations, warranties or obligations set forth in this Agreement; (B) any manufacture, sale, promotion, distribution, shipping, use of or exposure to the Product or any materials supplied by Client, including, without limitation,
product liability or strict liability; (C) Client’s exercise of control over the Services to the extent that Client’s instructions or directions violate applicable law; (D) any actual or alleged infringement or violation of any
patent, trade secret, copyright, trademark or other proprietary rights concerning the Product or provided by Client; or (E) any negligence or willful misconduct by Client, except to the extent that any of the foregoing arises out of or results
from any Cardinal Health Indemnitee’s negligence, willful misconduct or breach of this Agreement. 
 11.3    Indemnification
Procedures. All indemnification obligations in this Agreement are conditioned upon the Party seeking indemnification: (A) promptly notifying the indemnifying Party of any claim or liability of which the Party seeking indemnification becomes
aware (including a copy of any related complaint, summons, notice or other instrument); provided, however, that failure to provide such notice within a reasonable period of time shall not relieve the indemnifying Party of any of its obligations
hereunder except to the extent the indemnifying Party is prejudiced by such failure; (B) reasonably cooperating with the indemnifying Party in the defense of any such claim or liability (at the indemnifying Party’s expense); and
(C) not compromising or settling any claim or liability without prior written consent of the indemnifying Party. 
 ARTICLE 12

 LIMITATIONS OF LIABILITY 

[* * *] 

  
 10 

 ARTICLE 13 

INSURANCE 

13.1    Insurance Policies. During the term of this Agreement, Client shall obtain and maintain the following insurance with limits
not less than those specified below: 
 A.    Products and Completed Operations Liability Insurance covering the
Products included in this Agreement with a limit of not less than five million dollars US $5,000,000 per occurrence where upon non-emergency authorization by the United States Food and Drug Administration,
Client shall endeavor to obtain a limit of not less than ten million dollars US $10,000,000 per occurrence.; 
 B.    All-Risk Property Insurance, including transit coverage, in an amount equal to full replacement value covering Client’s property while it is at the 3PL Facility or in transit to or
from the 3PL Facility. Client’s all-risk property insurance shall apply to all losses and be primary (with respect both to any insurance issued to Cardinal Health and to any deductible amount or
self-insured amount retained by Cardinal Health) except for losses resulting solely from the gross negligence or willful misconduct of Cardinal Health. 

In the event that any of the required policies of insurance are written on a claims-made basis, then such policies shall be maintained during the entire term
of this Agreement and for a period of not more than three (3) years following the termination or expiration of this Agreement. 

13.2    Waiver. Client shall obtain a waiver from any insurance carrier with whom Client carries Property Insurance releasing its
subrogation rights against Cardinal Health except for losses resulting solely from the gross negligence or willful misconduct of Cardinal Health. Client shall not seek reimbursement for any property claim, or portion thereof that is not fully
recovered from Client’s property insurance except for losses resulting solely from the gross negligence or willful misconduct of Cardinal Health. 

13.3    Additional Insured Status. Cardinal Health, Inc., and its Affiliates shall be named as additional insureds under the
Products and Completed Operations Liability insurance policies as respects the Products and completed operations outlined in this Agreement. Such insurance shall be primary (with respect both to any insurance issued to Cardinal Health and to any
self-insured amount retained by Cardinal Health) with regard to Cardinal Health’s liability for damage arising out of those products for which they have been added as additional insureds. Such additional insurance status shall continue during
the term and, if the policies are written on a claims-made basis, shall continue for not more than three (3) years following termination or expiration of this Agreement. 

  
 11 

 13.4    Certificates. Client shall furnish certificates of insurance to Cardinal
Health evidencing the required insurance and additional insured status as soon as practicable after the Effective Date and within thirty (30) days after renewal of such policies. Client will endeavor to provide thirty (30) days written
notice of any cancellation prior to the policy(ies) expiration date(s). 
 ARTICLE 14 

NOTICES 
 All notices and other
communications hereunder shall be in writing and shall be deemed given: (A) when delivered personally; (B) when delivered by facsimile transmission (receipt verified); (C) when received or refused, if mailed by registered or certified mail
(return receipt requested), postage prepaid; or (D) when delivered if sent by express courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice; provided, that notices
of a change of address shall be effective only upon receipt thereof): 
  

			
	To Client:	  	 NeuroRx, Inc.
 913 North Market Street, Suite
200
 Wilmington, DE 19801
 Attn.: Jonathan Javitt, MD, MPH;
CEO

		
	With a copy to:	  	 NeuroRx, Inc.
 201 King of Prussia Road

Radnor, PA 19087
 Attn.: Robert Besthof, Head of
Operations

		
	To Cardinal Health:	  	 Cardinal Health 105, Inc.
 Third-Party
Logistics Services
 501 Mason Road, Suite 200
 La Vergne, TN
37086
 Attn: VP, Operations

		
	With a copy to:	  	 Cardinal Health, Inc.
 7000 Cardinal
Place
 Dublin, Ohio 43017
 Attn: Associate General Counsel

Facsimile: (614) 757-8919

 ARTICLE 15 

MISCELLANEOUS 

15.1    Entire Agreement; Amendments. This Agreement, the attachments and any amendments thereto constitute the entire
understanding between the Parties and supersede any contracts, agreements or understanding (oral or written) of the Parties with respect to the subject matter hereof. No term of this Agreement may be amended except upon written agreement of both
Parties, unless otherwise provided in this Agreement. 

  
 12 

 15.2    Captions. The captions in this Agreement are for convenience only and are
not to be interpreted or construed as a substantive part of this Agreement. 
 15.3    Further Assurances. The Parties agree to
execute, acknowledge and deliver such further instruments and to take all such other incidental acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement. 

15.4    No Waiver. Failure by either Party to insist upon strict compliance with any term of this Agreement in any one or more
instances shall not be deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure. 

15.5    Severability. If any term of this Agreement is declared invalid or unenforceable by a court or other body of competent
jurisdiction, the remaining terms of this Agreement shall continue in full force and effect. 
 15.6    Independent Contractors.
The relationship of the Parties is that of independent contractors, and neither Party shall incur any debts or make any commitments for the other Party except to the extent expressly provided in this Agreement. Nothing in this Agreement is intended
to create or shall be construed as creating between the Parties the relationship of joint venturers, co-partners, employer/employee or principal and agent. 

15.7    Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties, their successors and
permitted assigns. Neither Party may assign this Agreement, in whole or in part, without the prior written consent of the other Party, except that either Party may, without the other Party’s consent, assign this Agreement to an Affiliate or to
a successor to substantially all of the business or assets of the assigning company to which this Agreement relates. 

15.8    Governing Law. This Agreement shall be governed by and construed under the laws of the State of Delaware, excluding its
conflicts of law provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. 

15.9    Dispute Resolution. If any dispute, controversy or disagreement arises between the Parties
(“Dispute”), such Dispute shall be presented to the respective presidents or senior executives of Cardinal Health and Client for their consideration and resolution. If such Parties cannot reach a
resolution of the Dispute within sixty (60) days, either Party may submit the Dispute to a court of appropriate jurisdiction. 

15.10    Prevailing Party. In any dispute resolution proceeding between the Parties in connection with this Agreement, the
prevailing Party shall be entitled to its reasonable attorney’s fees and costs in such proceeding. 

  
 13 

 15.11    Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall constitute an original. 

15.12    Publicity. Neither Party shall make any press release or other public disclosure regarding this Agreement or the
transactions contemplated hereby without the other Party’s express prior written consent, except as required under applicable law or by any governmental agency, in which case the Party required to make the press release or public disclosure
shall use commercially reasonable efforts to obtain the approval of the other Party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or making the public disclosure. 

15.13    Setoff. Without limiting Cardinal Health’s rights under law or in equity, Cardinal Health and its Affiliates, parent
or related entities, collectively or individually, may exercise a right of set-off against any and all amounts due to Cardinal Health from Client. For purposes of this section. Cardinal Health, its Affiliates,
parent or related entities shall be deemed to be a single creditor. 
 15.14    Survival. The rights and obligations of the
Parties shall continue under Articles 10 (Confidentiality and Non-Use), to the extent expressly stated therein, 11 (Indemnification), 12 (Limitations of Liability), 13 (Insurance), to the extent expressly
stated therein, 14 (Notice) and 15 (Miscellaneous) and Section 6.4 (Effect of Termination), notwithstanding expiration or termination of this Agreement. 

15.15    Force Majesure. Except as to payments required under this Agreement, neither Party shall be liable in damages for, nor
shall this Agreement be terminable or cancelable by reason of, any delay or default in such Party’s performance hereunder if such default or delay is caused by events beyond such Party’s reasonable control including, but not limited to,
acts of God, regulation or law or other action or failure to act of any government or agency thereof, war or insurrection, civil commotion, destruction of production facilities or materials by earthquake, fire, flood or storm, labor disturbances,
epidemic, pandemic, or failure of suppliers, public utilities or common carriers; provided however, that the Party seeking relief hereunder shall immediately notify the other Party of such cause(s) beyond such Party’s reasonable control. The
Party that may invoke this section shall use all reasonable endeavors to reinstate its ongoing obligations to the other. If the cause(s) shall continue unabated for one hundred eighty (180) days, then both Parties shall meet to discuss and
negotiate in good faith what modifications to this Agreement should result from this force majeure. 
 [Signature Page to Exclusive
Distribution Agreement Follows] 

  
 14 

 IN WITNESS WHEREOF, the undersigned have caused their duly authorized representative to execute this
Agreement effective as of the date first written above. 
  

									
	CARDINAL HEALTH 105, INC.	 		 	NEURORX, INC.
					
	By:	 	/s/ Joel Wayment	 		 	By:	 	/s/ Jonathan Javitt
	Joel Wayment	 		 	Print Name:	 	Jonathan Javitt. MD, MPH
	VP, Operations	 		 	Title:	 	CEO
			
	Date: Sep 29, 2020	 		 	Date: Sept 25, 2020

 [Signature Page to Exclusive Distribution Agreement] 

  
 15 

 EXHIBIT A 

TRADITIONAL 3PL OPERATING GUIDELINES 

The OPG shall be finalized and mutually agreed upon between the Parties prior to the commercial launch of Product. Once finalized, a copy of the OPG shall be
attached hereto as Exhibit A and incorporated by reference. 

  
 16 

 EXHIBIT B 

FEE SCHEDULE 

[*    *    *] 

  
 17 

 TITLE MODEL ADDENDUM 

This Title Model Addendum (“Addendum”) is made as of the
25th day of September 2020 (“Effective Date”) between Cardinal Health 105, Inc. an Ohio corporation, with a place of business at 501 Mason Road, Suite 200, La Vergne, Tennessee,
37086 (“Cardinal Health”) and NeuroRx, Inc., a Delaware corporation whose principal mailing address is 913 North Market Street, Suite 200, Wilmington, Delaware 19801 Client”) each individually a
(“Party”) and collectively (the “Parties”). 
 RECITALS 

Cardinal Health and Client are Parties to an Exclusive Distribution Agreement dated the 25th day of
September 2020 (“Agreement”), pursuant to which Cardinal Health has agreed to provide third-party logistics services to Client. The terms of the Agreement specify that Client holds title to Product (as that term is
defined in the Agreement) and that Cardinal Health holds Products on consignment. Client is currently applying for and waiting to receive certain licenses necessary for Client to sell Products directly to Customers. In order to expedite
Client’s ability to sell Product to Customers throughout the Territory (as that term is defined in the Agreement), Cardinal Health has agreed to purchase and take title to Product on the terms set forth in this Addendum to the Agreement. 

THEREFORE, in consideration of the mutual covenants, terms and conditions set forth below, the Parties agree as follows: 

ARTICLE 1 
 TITLE MODEL
SERVICES 
 1.1    Title Model Services. During the Term of this Addendum, Cardinal Health will purchase and take
title to certain quantities of Product in accordance with the terms of this Addendum. The terms set forth in this Addendum shall apply only with respect to Product purchased from Client by Cardinal Health. 

1.2    Title Model Operating Guidelines. During the Term of this Addendum, Cardinal Health shall provide services as set
forth in the Title Model Operating Guidelines (“TMOPG”). The TMOPG shall be finalized and mutually agreed upon between the Parties prior to commercial launch of Product. Once finalized, a copy of the TMOPG shall be
attached hereto as Attachment 1 and incorporated by reference. 
 1.3    Max Purchased Inventory. Cardinal Health
will maintain between seven (7) and fourteen (14) DIOH (defined below) in order to meet Purchaser (defined below) demand for Product. Cardinal Health shall not purchase or hold in inventory more than fourteen (14) DIOH
(“Max Purchased Inventory”) unless mutually agreed upon in writing by both Parties. Inventory purchases exceeding the Max Purchased Inventory may be accomplished through an inventory pull form approved in writing by
Client. Until Purchaser demand for Product is determined using actual demand, DIOH will be determined using Client’s Twelve (12) Month Forecast. Thereafter (approximately four (4) months following first shipment to Purchasers), (i)
the term “DIOH” means the total number of units of Purchased Inventory (defined below) for a specific Product 

  
 1 

 
divided by Average Daily Sales of that Product, (ii) “Average Daily Sales” shall be determined by taking the total unit sales of a Product during the last four (4) complete
months and dividing that number by the number of business days in those four (4) months, and (iii) “Purchased Inventory’’ means Product which has been purchased by Cardinal Health and taken into its own
inventory in accordance with the terms of this Addendum. 
 1.4    Consigned Inventory. If Client desires for Cardinal
Health to store more than the Max Purchased Inventory quantity for any particular Product or if Client ships more than the Max Purchased Inventory level (“Consigned Inventory”), Client shall retain
title and risk of loss for such Consigned Inventory and Cardinal Health will hold the Consigned Inventory for Client on consignment until such time as Cardinal Health purchases all or a portion of the Consigned Inventory from Client. Consigned
Inventory will be segregated from Purchased Inventory and will be identified as Client property. 
 1.5    Delivery to
Cardinal Health and Title. 
 1.5.1    Delivery. Client shall deliver or cause to have delivered
Product to Cardinal Health at Cardinal Health’s facility located at 501 Mason Road, Suite 200, La Vergne, TN 37086 and/or 15 Ingram Boulevard, La Vergne, TN 37086 or to such other distribution facility as may be designated by Cardinal Health to
Client in writing (“3PL Facility”). Client shall be responsible for delivery of Product to the 3PL Facility, including all costs, expenses and risk of loss associated with such delivery. Cardinal Health will notify Client of
any identifiable damage to Product or shortage in quantity delivered within two (2) business days following (i) receipt of Product or (ii) discovery of any concealed damage or shortage. The Parties will work together in good faith to
determine the cause and extent of any such damage or shortage and shall endeavor to complete such review within thirty (30) days after Client’s receipt of notice in accordance with the preceding sentence. If any portion of the damaged
inventory has been invoiced to Cardinal Health in accordance with the terms of this Addendum, and if Cardinal Health and Client mutually agree that such damage or shortage is not due to the fault of Cardinal Health, Cardinal Health will deduct any
amounts due to Cardinal Health for Product damage or shortage against any amounts due from Cardinal Health to Client under Section 1.7.1 of this Addendum for Purchased Inventory. If any amount remains outstanding, Cardinal
Health will notify Client of such balance due and Client shall pay such balance due within fifteen (15) days of the date of notification. 

1.5.2    Title and Risk of Loss. 

1.5.2.1    Generally. Upon receipt of Product at the 3PL Facility, (i) title and risk of loss for
Product purchased by Cardinal Health (excluding Consigned Inventory) shall pass to Cardinal Health, and (ii) title and risk of loss for Consigned Inventory shall remain with Client until purchased by Cardinal Health in accordance with this
Addendum. 
 1.5.2.2    Mixed Shipment. In the event of loss, damage or destruction to Product in a
shipment that contains both Purchased Inventory and Consigned Inventory, but the Product has not yet been classified as either Purchased Inventory or Consigned Inventory, the damaged Product shall be deemed to be Consigned Inventory. Once Product is
definitively classified as Purchased Inventory or Consigned Inventory, title and risk of loss shall be as set forth in Section 1.5.2.1. Cardinal Health will use commercially reasonable efforts to receive Product either into
Purchased Inventory or into Consigned Inventory within one (1) business day following receipt of the Product at the 3PL Facility. 

  
 2 

 1.6    Forecast. During the term of this Addendum, not
less often than semi-annually, Client shall provide Cardinal Health with a twelve (12) month forecast of the volume of (i) units forecasted to be sold during the forecast period, (ii) orders for Product to be handled by Cardinal
Health, and (iii) Product (i.e. number of pallets) to be stored by Cardinal Health at the 3PL Facility (each a “Twelve (12) Month Forecast”). All Twelve (12) Month Forecasts, are non-binding and shall be used for the express purpose of operational planning. 

1.7    Cardinal Health’s Payment for Product. 

1.7.1    Invoice Price. Client will invoice Cardinal Health for Purchased Inventory at the wholesale
acquisition cost (“WAC”) in effect on the date of Cardinal Health’s purchase order for such Product. For clarity, Client has designated Cardinal Health to perform invoicing and other back office services for Client in
accordance with the terms of the Agreement and the TMOPG. As a result, Client’s invoices to Cardinal Health for Purchased Inventory will actually be generated by Cardinal Health on behalf of Client. Except as otherwise provided in
Section 1.12.2, payment of each such undisputed invoice shall be due as follows: thirty-four (34) days following date of invoice for payments made via electronic funds transfer (EFT), and thirty days following date of invoice for
payments made via check; provided, however that if payment is due on a Saturday, Sunday or federal holiday, such invoice shall be due and payable on the next business day. 

1.7.1.1     WAC Decrease. If at any time during the term of this Addendum, Client decreases the WAC for any
Purchased Inventory, then Cardinal Health shall deduct an amount equal to the difference between (i) the value of Cardinal Health’s then-current Purchased Inventory of that Product determined using WAC as of the date Cardinal Health
purchased that Product, and (ii) the value of Cardinal Health’s then-current Purchased Inventory of that Product, determined using the new, decreased WAC, against any amounts due from Cardinal Health to Client for Purchased Inventory. 

1.7.1.2    WAC Increase. If at any time during the term of this Addendum, Client increases the WAC for any
Purchased Inventory, Cardinal Health shall be entitled to retain the value of the WAC increase for Cardinal Health’s then-current inventory of that Product. For purposes of this Section, “Cardinal Health’s then-current inventory”
shall include all inventory of Products held in Cardinal Health’s 3PL Facility(ies), and all Products “in transit” to or from such 3PL Facility(ics) on the effective date of such price increase, excluding any Product that would be
deemed to be Consigned Inventory in accordance with this Addendum. In the event Product is backordered at the time of the WAC increase, Cardinal Health will be charged in accordance with Section 1.7.1. 

1.7.1.3    Patient Assistance Program Purchases. If at any time during the term of this Addendum, Client
wishes for Cardinal Health to purchase Product for Client’s Patient Assistance Program, Cardinal Health will purchase such Product from Client at zero dollars. Client will incur the transactional fees set forth on the Fee Schedule for such
inventory purchases. 

  
 3 

 1.8    Client’s Payment for Services. 

1.8.1    Service Fees. In consideration of the Services provided pursuant to this Addendum, Client shall pay
to Cardinal Health the State Licensure Service Fee set forth on the Fee Schedule. The State Licensure Service Fee shall only apply during the term of this Addendum. Cardinal Health may deduct the State Licensure Service Fee from any amounts due to
Client for Purchased Inventory. With respect to all other Fees (excluding the State Licensure Fee), Cardinal Health may also deduct such Fees from any amounts due to Client for Purchased Inventory, but only if Client has not paid such Fees by the
due date specified in Section 5.2 of the Agreement. If any amount of Fees remains outstanding after Cardinal Health has deducted such Fees pursuant to this Section 1.8, Cardinal Health will notify Client of such balance due and Client
shall promptly pay such balance to Cardinal Health. 
 1.9    Client’s Third-Party Agreements. Cardinal Health
recognizes that Client may enter into agreements with Purchasers (defined in Section 1.13.1) related to the Products. Such agreements may include without limitation distribution service agreements with wholesalers, pricing agreements with
Purchasers and group purchasing organizations, and other types of agreements. Client shall not enter into any such agreements on Cardinal Health’s behalf and shall not agree to any terms that would be binding on Cardinal Health without Cardinal
Health’s prior written consent. If any Purchaser invoices Cardinal Health or deducts from Cardinal Health for any fee or other charge related to the Product or an agreement entered into by Client with such Purchaser and Cardinal Health elects
in its sole discretion to pay such Purchaser invoice, then Cardinal Health will deduct any amounts due to Cardinal Health under this Section 1.9 against any amounts due from Cardinal Health to Client for Purchased
Inventory. If any amount still remains outstanding, Cardinal Health will notify Client of such balance due and Client shall pay such balance due within fifteen (15) days of the date of notification. 

1.10    Cardinal Health Terms and Conditions of Sale. Cardinal Health has the right to (i) establish terms and
conditions of sale of the Product to Purchasers, and (ii) refuse sale to any third party who does not agree to such terms and conditions of sale. 

1.11    Third-Party Credit Approval. Client recognizes that the Purchasers are customers of Cardinal Health and are subject
to Cardinal Health’s standard practices for credit review and approval. Proposed Purchasers may be required to complete and sign a Cardinal Health credit application prior to any purchase from Cardinal Health. In such instance, Cardinal Health
will exercise reasonable commercial efforts to complete such credit review and approval process within a reasonable period of time, provided that the proposed Purchaser provides all necessary information, meets Cardinal Health credit standards, and
signs the Cardinal Health credit application. 
 1.12    Third-Party Payment Terms. 

1.12.1    Third-party wholesalers and other Purchasers may expect or require Cardinal Health to provide payment
terms that are the same as those agreed to by Client in its agreements with such Purchaser. Cardinal Health will provide payment terms of net thirty (30) to Purchasers with approved credit. If Client has agreed to provide a Purchaser a cash
discount for purchases paid within thirty (30) days, Cardinal Health will honor such cash discount and will deduct the 

  
 4 

 
amount of any cash discount taken by a Purchaser against the next payments due from Cardinal Health to Client for Purchased Inventory. If the amount due to Cardinal Health under this Section has
not been fully paid through deduction as described in the preceding sentence, Cardinal Health will notify Client of such amount due and Client shall pay such balance due within fifteen (15) days of the date of notification. Client will be
responsible to reimburse Cardinal Health the amount of any cash discount retained by a Purchaser, even if Client or Cardinal Health believe that a particular cash discount was not properly taken by such Purchaser. 

1.12.2    If Client desires for Cardinal Health to provide greater than thirty (30) day payment terms
(“Extended Terms”) to Purchasers for any Product, then Cardinal Health’s written consent to such Extended Terms shall first be required. Cardinal Health may elect not to provide Extended Terms to Purchasers that do not meet
Cardinal Health’s credit requirements. Cardinal Health shall periodically evaluate its payment terms to Client and if Product sales by Cardinal Health to Purchasers result in Blended Terms (as defined below) greater than Cardinal Health’s
current payment terms to Client, Cardinal Health will modify its current payment terms to Client to an amount not to exceed the Blended Terms plus fifteen (15) days. Cardinal Health will provide Client with written notice of such change in
Cardinal Health’s payment terms to Client. “Blended Terms” means payment terms which are calculated as follows: each payment term Client has extended to Purchasers of Product is multiplied by the percentage representing
total sales volume to Purchasers with that payment term, and the resulting amounts are added together. For example, if Client has extended three different payments terms to Purchasers of Product as follows: (Net 30 which represents $10 million
in sales, Net 60 which represents $30 million in sales, and Net 90 which represents $10 million in sales); then as a percentage, 20% of sales are paid in 30 days, 60% of sales are paid in 60 days, and 20% of sales are paid in 90 days. The
combination of (.2*30 + .6*60 + .2*90) results in Blended Terms of sixty (60) days, so Cardinal Health’s payment terms to Client shall be net seventy-five (75) days. 

1.13    Product Returns and Replacement. 

1.13.1    Purchaser Returns. All Product returned to Cardinal Health by Purchasers shall be processed and
handled by Cardinal Health in accordance with the TMOPG and Client’s returned goods policy (“RGP”). If a Purchaser return is permitted by the RGP, Cardinal Health will accept the return and credit the Purchaser in accordance
with the RGP. If a Purchaser Return is not permitted by the RGP (an “Invalid Return”), Cardinal Health will not authorize the Invalid Return and will not credit the Purchaser for such Invalid Return. If a Purchaser deducts value for
an Invalid Return, Cardinal Health will use commercially reasonable efforts to resolve the matter with the Purchaser, but if Cardinal Health is not reasonably able to collect for the Invalid Return, Cardinal Health will deduct any amounts the
Purchaser deducts from Cardinal Health under this Section 1.13.1 against any amounts due from Cardinal Health to Client for Purchased Inventory. All Product returned by Purchasers will be destroyed by Cardinal Health’s designated
third-party waste destruction subcontractor and Cardinal Health will invoice Client for destruction costs. For purposes of this Addendum, the term “Purchaser” means any third party which purchases Product from Cardinal Health. 

1.13.2    CVS Returns. In the event that CVS Health or one of its affiliates (“CVS”) is a
Purchaser, Cardinal Health will attempt to administer the returns in accordance with the RGP. Client acknowledges, however, that CVS typically administers ALL returns in accordance with 

  
 5 

 
the CVS returned goods policy. If CVS deducts any amount from Cardinal Health in connection with a return (whether or not such return is an Invalid Return), Cardinal Health will deduct the amount
of the CVS deduction against any amounts due from Cardinal Health to Client for Purchased Inventory. 

1.13.3    Cardinal Health Returns. With respect to any Purchased Inventory, Cardinal Health shall have the
right to (i) return title to Client for any Purchased Inventory and (ii) in the case of any return of Purchased Inventory by Cardinal Health, deduct any amounts due to Cardinal Health against any amounts due from Cardinal Health to Client
for Purchased Inventory. If any amount remains outstanding, Cardinal Health will notify Client of such balance due and Client shall pay such balance due within fifteen (15) days of the date of notification. If Client dispositions any Cardinal
Health returned Product for destruction, then such Product will be destroyed by Cardinal Health’s designated third-party vendor. Cardinal Health will deduct any amounts due for such destruction against any amounts due from Cardinal Health to
Client for Purchased Inventory. 
 1.13.4    Expiration or Termination. Upon expiration or termination of
this Addendum, Cardinal Health shall return to Client or its designee in accordance with Section 1.13.3 all Purchased Inventory and Consigned Inventory. Fees related to such Purchased Inventory and already incurred by
Client shall not be reimbursed. 
 1.13.5    Product Replacement. If Cardinal Health is required to
replace Product for a Purchaser, Cardinal Health shall send the replacement Product to such Purchaser. Cardinal Health shall deduct for the WAC value of such replacement against any amounts due from Cardinal Health to Client for Purchased Inventory
except where such replacement is due to an actual shortage in the quantity delivered due to the fault of Cardinal Health or due to Product damage or loss to the extent resulting due to the fault of Cardinal Health. 

1.13.6    Deductions. Cardinal Health will deduct any amounts due to Cardinal Health under Sections
1.13.1 through 1.13.5 against any amounts due from Cardinal Health to Client for Purchased Inventory. If any amount remains outstanding, Cardinal Health will notify Client of such balance due and Client shall pay such balance due within fifteen
(15) days of the date of notification. 
 1.13.7    Additional Services. Any customization or
additional return services requested by Client and not identified in the TMOPG shall be performed at an additional fee as agreed by the Parties. 

1.14    True-Up on Pricing Variances/Chargebacks; Chargeback Advances. If Client
enters into an agreement with a Purchaser that provides for a price that is lower than the price paid by Cardinal Health for such Product, Cardinal Health shall honor such lower price notwithstanding any provision herein to the contrary and Client
shall pay to Cardinal Health the difference between the higher price paid by Cardinal Health and the lower price sold to Purchaser (the “Chargeback”). Client must provide Cardinal Health with a Chargeback advance to cover credit
exposure of unsecured credit granted to Client by Cardinal Health for Chargeback claims and to offset the carrying costs in the Chargeback process, subject to the following conditions: (i) the Chargeback advance, which Cardinal Health will
calculate each calendar quarter, must be no less than an amount equal to one (1) month of Chargeback billings based on an average of the most recent 

  
 6 

 
six (6) months’ billings; and (ii) Cardinal Health will remit any Chargeback advance that remains at the conclusion of the given calendar quarter in the next payment due to Client for
Purchased Inventory following that calendar quarter. Cardinal Health will deduct any amounts due to Cardinal Health under this Section 1.14 against any amounts due from Cardinal Health to Client for Purchased Inventory. If
any amount remains outstanding, Cardinal Health will notify Client of such balance due and Client shall pay such balance due within fifteen (15) days of the date of notification. 

1.15    Financial Statements. Client shall upon request, provide Cardinal Health with Client’s most recent audited
year-end consolidated financial statements and quarterly year-to-date updates to such financial statements. 

1.16    Debit Balances. If Client is in a debit balance position with Cardinal Health, Cardinal Health reserves the right to
request payment by alternative means (including, but not limited to, inventory or cash payments). Client will then cause Cardinal Health to receive payment in full no later than thirty (30) days following such request. Cardinal Health retains
the right to: (i) withhold payments to Client, (ii) set-off amounts owed to Client against amounts owed to Cardinal Health pursuant to Section 15.13 of the Agreement, and/or
(iii) terminate this Addendum or the Agreement pursuant to Section 6.2(B) of the Agreement if Cardinal Health does not receive payments for amounts owed to it under this Agreement or based upon credit or other considerations deemed
relevant by Cardinal Health. 
 1.17    Guaranty. As an inducement for Cardinal Health to provide the Services to Client,
Client agrees to provide to Cardinal Health if applicable and upon request, a fully executed Unconditional Guaranty agreement from its parent corporation (if applicable) or another affiliate entity as deemed appropriate by Cardinal Health. 

1.18    Security Agreement. If, notwithstanding the intention of the Parties, the sale of the Product to Cardinal Health
pursuant to this Addendum shall be characterized as a consignment and not a sale, then Cardinal Health and Client intend that this Addendum constitutes a security agreement under applicable law and Client shall be deemed to have granted to Cardinal
Health a security interest in all right, title and interest of the Client in, to and under the Product to secure the purchase price paid by Cardinal Health for the Product and all fees, costs and other amounts due under the Agreement, whether now
existing or hereafter arising. The security interest in the Product shall continue until the Addendum has terminated and all obligations have been indefeasible paid in full. The Client consents to the filing of financing statements in favor of
Cardinal Health along with any other documents necessary to perfect Cardinal Health’s security interest in the Product. 
 ARTICLE 2

 MISCELLANEOUS 

2.1    Term. Either Party may terminate this Addendum on sixty (60) days prior written notice. 

2.2    Applicability of Agreement. The terms of the Agreement shall apply to the Services performed in this Addendum. In the
event of a conflict between the terms of the Agreement and the terms of this Addendum, the terms of this Addendum shall govern. 

  
 7 

 2.3    Capitalized Terms. Capitalized terms not otherwise defined herein
shall have the meaning set forth in the Agreement. 
 IN WITNESS, WHEREOF, the undersigned have caused their duly authorized
representative to execute this Addendum effective as of the date first written above. 
  

									
	CARDINAL HEALTH 105, INC,	 		 	NEURORX, INC.
					
	 By:
  
	 	 /s/ Joel Wayment
	 		 	 By:
  
	 	 /s/ Jonathan Javitt

	Joel Wayment	 		 	Print Name:	 	Jonathan Javitt, MD, MPH
	VP, Operations	 		 	Title:	 	CEO
					
	Date:	 	Sep 29, 2020	 		 	Date:	 	September 25, 2020

 [Signature page to Title Model Addendum] 

  
 8 

 ATTACHMENT 1 

TITLE MODEL OPERATING GUIDELINES 
 The
TMOPG shall be finalized and mutually agreed upon between the Parties prior to commercial launch of Product. Once finalized, a copy of the TMOPG shall be attached hereto as Attachment 1 and incorporated by reference. 

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]